CHARACTERIZATION OF BURKITT'S LYMPHOMA CELL LINES WITH MONOCLONAL ANTIBODIES USING AN ELISA TECHNIQUE NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


CHARACTERIZATION OF BURKITT'S LYMPHOMA CELL LINES WITH MONOCLONAL ANTIBODIES USING AN ELISA TECHNIQUE

Leukocyte Typing II; 2:403-10 1986. Unique Identifier : AIDSLINE ICDB/87626870
Sandlund JT; Kiwanuka J; Marti GE; Goldschmidts W; Magrath IT; Pediatric Branch, Clinical Oncology Program, Div. of Cancer; Treatment, NCI, NIH, Bethesda, MD 20205

Abstract: Using an enzyme-linked immunosorbent assay (ELISA) technique, the B cell/leukemia panel of murine monoclonal antibodies (mAbs) from the Second International Workshop on Human Leukocyte Differentiation Antigens was screened against 18 undifferentiated lymphoma (UL) cell lines (African Burkitt's lymphoma, 6; American Burkitt's lymphoma, 7; and UL/non-Burkitt's type, 5), two normal lymphoblastoid cell lines, and one cord blood lymphoblastoid cell line. In addition, three of the American Burkitt's lymphoma cell lines were re-screened with the same mAb panel by flow cytometry. The majority of the lymphoma cell lines studied reacted with mAbs detecting B cell cluster group proteins p95, p35, p135 (CD19, 10, 22), p45/55/65, p29/34, and p220. In addition, most cell lines reacted with non-clustered B cell mAbs B23 (8B1), B32 (9BA-5), B42 (B-7), B10 (RW35-1C5), B44 (HB6), B45 (HB4), and B52 (41H16). Similar reactivity observed with mAbs detecting leukemia panel cluster groups CD10 (CALLA), CD29 (p24), the transferrin receptor, and the non-clustered antibody L7. With this panel no phenotypic differences among the subgroups of cell lines could be discerned with ELISA. Within each cluster group, marked variation in reactivity among the individual mAbs was seen with both techniques, suggesting that the antigens they bind in lymphoma cells may vary with regard to the presence or accessibility of different epitopes. Some differences also were seen that related to the technique used. The pattern of reactivity observed is consistent with the possibility that Burkitt's lymphoma originates from an immature B cell. (9 Refs)
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Antibodies, Monoclonal/DIAGNOSTIC USE/*IMMUNOLOGY Antibody Specificity Antigens, Neoplasm/IMMUNOLOGY Antigens, Surface/IMMUNOLOGY B-Lymphocytes/IMMUNOLOGY Burkitt's Lymphoma/DIAGNOSIS/*IMMUNOLOGY Cell Line Comparative Study *Enzyme-Linked Immunosorbent Assay Flow Cytometry Fluorescent Antibody Technique Herpesvirus 4, Human/IMMUNOLOGY Human Tumor Virus Infections/IMMUNOLOGY MEETING PAPER

KWDacquiredimmunodeficiencysyndrome/immunologyantibodies,monoclonal/diagnosticuse/KWDimmunologyantibodyspecificityantigens,neoplasm/immunologyantigens,surface/immunologyb-lymphocytes/immunologyburkitt'slymphoma/diagnosis/KWDimmunologycelllinecomparativestudyKWDenzyme-linkedimmunosorbentassayflowcytometryfluorescentantibodytechniqueherpesvirus4,human/immunologyhumantumorvirusinfections/immunologymeetingpaper
870228
M8720253

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .